Posted by Michael Wonder on 04 Sep 2024
Iptacopan hydrochloride for the treatment of patients with paroxysmal nocturnal haemoglobinuria
4 September 2024 - NICE has published final evidence-based recommendations on the use of iptacopan hydrochloride (Fabhalta) for the treatment of adults with paroxysmal nocturnal haemoglobinuria.
Iptacopan hydrochloride is recommended as an option for the treatment of adults with paroxysmal nocturnal haemoglobinuria with haemolytic anaemia. Iptacopan hydrochloride is only recommended if Novartis provides it according to the commercial arrangement.
